Vesicular stomatitis virus (VSV) is an antigenic peptide fragment of VSV that binds the LDL receptor. VSV exhibits anticancer chemotherapeutic potential. VSV is used as a vector to express tumor-targeting ligands, allowing the virus to target, infect, and kill tumor cells. VSV inhibits myeloma growth in vivo and also kills a variety of neuroendocrine cells in vitro and in vivo.
| Purity | ≥95% |
|---|---|
| Formula | C44H66N12O12 |
| Formula Wt. | 955.09 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | V1872 Info Sheet PDF |
|---|
Ammayappan A, Peng KW, Russell SJ. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands. J Virol. 2013 Dec;87(24):13543-55. PMID: 24089573.
Randle RW, Northrup SA, Sirintrapun SJ, et al. Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors. Surgery. 2013 Dec;154(6):1323-29; discussion 1329-30. PMID: 23973113.
Naik S, Nace R, Barber GN, et al. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther. 2012 Jul;19(7):443-50. PMID: 22522623.
